<DOC>
	<DOC>NCT02549417</DOC>
	<brief_summary>This study is designed to evaluate efficacy and safety of KHK7580 orally administered once daily for 32 weeks for patients with secondary hyperparathyroidism receiving peritoneal dialysis. After 32-week treatment period, the subjects will receive KHK7580 in the 20-week extension period to evaluate long-term safety and efficacy.</brief_summary>
	<brief_title>Phase 3 Study of KHK7580</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<criteria>Personally submitted written voluntary informed consent to participate in the study Stable chronic renal disease treated with peritoneal dialysis for at least 16 weeks before screening Intact PTH level of &gt; 240 pg/ml at screening Treatment with cinacalcet hydrochloride within 2 weeks before screening; Change in dose or dosing regimen of an activated vitamin D drug or its derivative, phosphate binder, or calcium preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening; Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening; Severe heart disease; Severe hepatic dysfunction; Uncontrolled hypertension and/or diabetes; Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening; Primary hyperparathyroidism; Other conditions unfit for participation in this study at the discretion of the investigator or subinvestigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>